Literature DB >> 22923097

Management of tachyarrhythmias in children.

Amy N McCammond1, Seshadri Balaji.   

Abstract

OPINION STATEMENT: Management of tachycardia in children depends on the accurate characterization of the origin and mechanism of the rhythm, which can usually be achieved using noninvasive tests such as an electrocardiogram, Holter or cardiac event monitoring. Supraventricular tachycardia (SVT), the most common tachyarrhythmia in children, is most often due to an accessory pathway or dual AV nodal pathways. Adenosine and vagal maneuvers are useful to diagnose and terminate an acute event. Long-term management options include prophylactic drug therapy (aimed at suppressing the tachyarrhythmia) and catheter ablation. Ablation for SVT is highly successful with a low complication rate, and is first-line therapy in older patients. Ventricular arrhythmias are fortunately uncommon in children with normal hearts, and are seen primarily in the setting of abnormal myocardium and inherited ion channel defects. Management options for ventricular rhythms include drugs, catheter ablation and implantable cardioverter-defibrillators (ICDs). ICDs are indicated in patients with a risk of sudden death due to an arrhythmia.

Entities:  

Year:  2012        PMID: 22923097     DOI: 10.1007/s11936-012-0199-0

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  22 in total

1.  The ice bag: a new technique for interruption of supraventricular tachycardia.

Authors:  G S Bisset; W Gaum; S Kaplan
Journal:  J Pediatr       Date:  1980-10       Impact factor: 4.406

2.  Beta-blocker efficacy in high-risk patients with the congenital long-QT syndrome types 1 and 2: implications for patient management.

Authors:  Ilan Goldenberg; James Bradley; Arthur Moss; Scott McNitt; Slava Polonsky; Jennifer L Robinson; Mark Andrews; Wojciech Zareba
Journal:  J Cardiovasc Electrophysiol       Date:  2010-03-05

3.  Survey of current practice of pediatric electrophysiologists for asymptomatic Wolff-Parkinson-White syndrome.

Authors:  Robert M Campbell; Margaret J Strieper; Patricio A Frias; Kathryn K Collins; George F Van Hare; Anne M Dubin
Journal:  Pediatrics       Date:  2003-03       Impact factor: 7.124

4.  Radiofrequency catheter ablation of atrioventricular nodal reentrant tachycardia in children.

Authors:  O H Teixeira; S Balaji; C L Case; P C Gillette
Journal:  Pacing Clin Electrophysiol       Date:  1994-10       Impact factor: 1.976

5.  Prospective assessment after pediatric cardiac ablation: demographics, medical profiles, and initial outcomes.

Authors:  George F Van Hare; Harold Javitz; Dorit Carmelli; J Philip Saul; Ronn E Tanel; Peter S Fischbach; Ronald J Kanter; Michael Schaffer; Ann Dunnigan; Steven Colan; Gerald Serwer
Journal:  J Cardiovasc Electrophysiol       Date:  2004-07

6.  Mexiletine: an effective antiarrhythmic drug for treatment of ventricular arrhythmias in congenital heart disease.

Authors:  J P Moak; R T Smith; A Garson
Journal:  J Am Coll Cardiol       Date:  1987-10       Impact factor: 24.094

7.  Therapeutic and diagnostic utility of adenosine during tachycardia evaluation in children.

Authors:  J E Crosson; S P Etheridge; S Milstein; P S Hesslein; A Dunnigan
Journal:  Am J Cardiol       Date:  1994-07-15       Impact factor: 2.778

8.  Radiofrequency catheter ablation of incessant, medically resistant supraventricular tachycardia in infants and small children.

Authors:  C L Case; P C Gillette; P C Oslizlok; B J Knick; H L Blair
Journal:  J Am Coll Cardiol       Date:  1992-11-15       Impact factor: 24.094

Review 9.  Supraventricular arrhythmias in children.

Authors:  P C Gillette
Journal:  J Am Coll Cardiol       Date:  1985-06       Impact factor: 24.094

10.  Flecainide as first-line treatment for supraventricular tachycardia in newborns.

Authors:  Marco Ferlini; Anna M Colli; Carla Bonanomi; Laura Salvini; Maria A Galli; Patrizia Salice; Romana Ravaglia; Marco Centola; Gian B Danzi
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2009-05       Impact factor: 2.160

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.